Nobuyuki Miyasaka Selected Research

Vasculitis (Vasculitides)

1/2019	Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.
4/2017	A sphingosine 1-phosphate receptor agonist ameliorates animal model of vasculitis.
1/2016	Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study.
2/2013	Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nobuyuki Miyasaka Research Topics

Disease

104	Rheumatoid Arthritis 03/2021 - 10/2002
19	Arthritis (Polyarthritis) 02/2016 - 10/2002
14	Infections 01/2021 - 01/2007
14	Inflammation (Inflammations) 01/2019 - 06/2004
13	Polymyositis 01/2018 - 12/2003
12	Dermatomyositis (Dermatopolymyositis) 01/2020 - 06/2002
11	Myositis (Idiopathic Inflammatory Myopathies) 01/2018 - 04/2007
11	Experimental Arthritis 01/2016 - 10/2002
10	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 01/2020 - 01/2005
9	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020 - 06/2002
4	Rheumatic Diseases (Rheumatism) 01/2020 - 10/2011
4	Vasculitis (Vasculitides) 01/2019 - 02/2013
4	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 02/2008
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2016 - 01/2007
3	Necrosis 01/2020 - 07/2011
3	Neoplasms (Cancer) 09/2016 - 02/2008
3	Drug-Related Side Effects and Adverse Reactions 01/2016 - 06/2012
3	Lupus Nephritis 01/2016 - 09/2003
3	Opportunistic Infections (Opportunistic Infection) 11/2012 - 01/2005
2	Churg-Strauss Syndrome (Allergic Angiitis) 04/2019 - 07/2014
2	Herpes Zoster 09/2018 - 01/2017
2	Fever (Fevers) 01/2016 - 01/2015
2	Crohn Disease (Crohn's Disease) 01/2016 - 09/2014
2	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2016 - 10/2012
2	Osteoarthritis 10/2014 - 11/2002
2	Hepatitis 01/2014 - 01/2008
2	Immunoglobulin G4-Related Disease 11/2013 - 08/2011
2	Retroperitoneal Fibrosis 11/2013 - 08/2011
2	Glomerulonephritis 07/2013 - 12/2010
2	Bacterial Infections (Bacterial Infection) 06/2013 - 06/2009
2	Lung Diseases (Lung Disease) 11/2012 - 11/2012
2	Nephritis 12/2010 - 01/2009

Drug/Important Bio-Agent (IBA)

29	Methotrexate (Mexate)FDA LinkGeneric 03/2020 - 01/2006
21	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 12/2004
19	Biological ProductsIBA 09/2018 - 01/2006
17	Antirheumatic Agents (DMARD)IBA 09/2018 - 09/2007
16	Infliximab (Remicade)FDA Link 01/2020 - 01/2005
15	Etanercept (Enbrel)FDA Link 03/2021 - 01/2005
13	Proteins (Proteins, Gene)FDA Link 01/2018 - 10/2002
12	tocilizumab (atlizumab)FDA Link 05/2020 - 09/2007
12	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2018 - 09/2003
12	Adalimumab (Humira)FDA Link 01/2017 - 01/2008
12	CytokinesIBA 02/2015 - 11/2002
10	Tacrolimus (Prograf)FDA LinkGeneric 01/2021 - 02/2008
10	Interleukin-6 (Interleukin 6)IBA 01/2016 - 06/2004
9	Certolizumab Pegol FDA Link 03/2020 - 07/2014
8	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 06/2002
8	Tumor Necrosis Factor InhibitorsIBA 09/2018 - 01/2009
7	AntibodiesIBA 01/2017 - 12/2002
6	Pharmaceutical PreparationsIBA 05/2021 - 06/2012
6	golimumab FDA Link 09/2018 - 06/2012
6	Abatacept (Orencia)FDA Link 09/2017 - 03/2013
6	Therapeutic UsesIBA 07/2017 - 01/2005
6	ChemokinesIBA 02/2015 - 01/2009
6	LigandsIBA 09/2014 - 11/2002
6	Monoclonal AntibodiesIBA 03/2014 - 10/2005
5	AutoantibodiesIBA 01/2017 - 12/2002
5	Intravenous Immunoglobulins (IVIG)FDA Link 07/2015 - 12/2003
5	Immunoglobulin G (IgG)IBA 08/2014 - 12/2002
5	Collagen Type II (Type II Collagen)IBA 08/2014 - 10/2002
4	C-Reactive ProteinIBA 01/2021 - 06/2013
4	GlucocorticoidsIBA 01/2020 - 01/2009
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2019 - 01/2008
4	Immunosuppressive Agents (Immunosuppressants)IBA 04/2019 - 08/2005
4	Interleukin-17 (Interleukin 17)IBA 01/2016 - 08/2009
4	Rituximab (Mabthera)FDA Link 01/2016 - 01/2007
4	Biomarkers (Surrogate Marker)IBA 05/2015 - 01/2009
4	Messenger RNA (mRNA)IBA 10/2014 - 03/2002
4	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2012 - 11/2003
3	lysophosphatidic acidIBA 01/2019 - 08/2013
3	Lysophosphatidic Acid ReceptorsIBA 01/2019 - 08/2013
3	Peptides (Polypeptides)IBA 07/2017 - 07/2015
3	RetinoidsIBA 02/2013 - 10/2009
3	tamibaroteneIBA 02/2013 - 10/2009
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 11/2012 - 07/2006
3	Chemokine CX3CL1IBA 03/2012 - 12/2004
3	SteroidsIBA 01/2008 - 06/2002
2	Trimethoprim (Proloprim)FDA LinkGeneric 01/2020 - 01/2017
2	Thymidine Monophosphate (TMP)IBA 01/2020 - 01/2017
2	Sulfamethoxazole FDA LinkGeneric 01/2020 - 01/2017
2	LipidsIBA 01/2019 - 08/2013
2	AutoantigensIBA 07/2017 - 07/2015
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2017 - 07/2015
2	CollagenIBA 02/2016 - 10/2015
2	InterleukinsIBA 01/2016 - 06/2010
2	Interleukin-4 (Interleukin 4)IBA 01/2016 - 10/2009
2	InterferonsIBA 01/2016 - 06/2010
2	Peptide Hydrolases (Proteases)FDA Link 01/2016 - 11/2003
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2016 - 10/2012
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2015 - 08/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2014 - 01/2008
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 12/2002
2	Complement System Proteins (Complement)IBA 11/2013 - 01/2009
2	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2012 - 07/2006
2	Creatine Kinase (Creatine Phosphokinase)IBA 06/2012 - 12/2003
2	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 04/2011 - 01/2005
2	Myosins (Myosin)IBA 10/2009 - 11/2005

Therapy/Procedure

35	Therapeutics 03/2020 - 06/2002
2	Intraperitoneal Injections 04/2017 - 02/2013
2	Biological Therapy 05/2015 - 11/2012